TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options for Untreated ALL
Source: Acute Lymphoblastic Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 17, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Untreated ALL
Treatment options for untreated acute lymphoblastic leukemia (ALL) include:
Remission induction therapy, including:
Source links and citations
Remission induction therapy, including:
Combination chemotherapy.
Remission induction therapy, including:
Imatinib mesylate (for patients with Philadelphia chromosome [Ph]–positive ALL).
Remission induction therapy, including:
Imatinib mesylate combined with combination chemotherapy (for patients with Ph-positive ALL).
Remission induction therapy, including:
Supportive care.
Central nervous system (CNS) prophylaxis therapy, including:
Source links and citations
Central nervous system (CNS) prophylaxis therapy, including:
Cranial radiation therapy plus intrathecal (IT) methotrexate.
Central nervous system (CNS) prophylaxis therapy, including:
High-dose systemic methotrexate and IT methotrexate without cranial radiation therapy.
Central nervous system (CNS) prophylaxis therapy, including:
IT chemotherapy alone.
Continue within this section
Preserved source evidence · Not medical advice